Skip to main content

Advertisement

Table 1 Characteristics of MSM study participants at enrolment into CANOC (n = 2858)

From: Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort

Characteristic Total (%)a
Province
 British Columbia 854 (30)
 Ontario 1045 (37)
 Quebec 959 (34)
Age (years) 40 (34–46)
Ethnicity
 Caucasian 1320 (46)
 Black 51 (2)
 Aboriginal 70 (2)
 Other 371 (13)
 Unknown 1046 (37)
History of IDU
 No 2555 (89)
 Yes 247 (9)
 Unknown 56 (2)
Hepatitis C status
 No 2413 (84)
 Yes 331 (12)
 Unknown 114 (4)
Era of cART initiation
 2000–2003 729 (26)
 2004–2007 931 (33)
 2008–2012 1198 (42)
Number of viral load tests per year
 Less than 3 583 (20)
 3–4 1590 (56)
 5–6 360 (13)
 More than 6 325 (11)
Initial 3rd ARV class
 NNRTI 1277 (45)
 Unboosted PI 128 (4)
 Boosted PI 1239 (43)
 Other 214 (7)
Initial 3rd ARV
 Nevirapine 252 (9)
 Efavirenz 1033 (36)
 Lopinavir 424 (15)
 Atazanavir 578 (20)
 Other 571 (20)
NRTI combination
 Tenofovir/emtricitabine 1217 (43)
 Zidovudine/lamivudine 594 (21)
 Tenofovir/lamivudine 207 (7)
 Abacavir/lamivudine 468 (16)
 Stavudine/lamivudine 212 (7)
 Other 160 (6)
AIDS-defining illness
 No 2284 (80)
 Yes 459 (16)
 Unknown 115 (4)
Viral load (log10 copies/mL) 4.96 (4.51–5.00)
CD4 count (cells/uL) 230 (130–321)
  1. ARV antiretroviral, IDU injecting drug use, NNRTI nonnucleoside reverse transcriptase inhibitor, PI protease inhibitor
  2. aResults are presented as n (%) with the exception of age, viral load, and CD4 count, for which median (Q1–Q3) is shown. Percentages may not equal 100 % as a result of rounding